Saturday, May 21, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Researchers examine benefits of lateral flow testing with regards to the new Paxlovid drug for treatment of COVID-19

by Medical Finance
in Coronavirus
Study: The impact of recurrent rapid test strategies on the effectiveness of at-home antiviral treatments for SARS-CoV-2. Image Credit: Cryptographer/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Lateral flow devices, or lateral flow tests, have played a significant role in helping to identify infectious individuals during the coronavirus disease 2019 (COVID-19) pandemic. They have been key for scaling down restrictions designed to reduce the transmission of the disease, allowing individuals to test regularly and isolate before infecting others, as well as reducing the amount of unnecessary isolation from those who display symptoms similar to those seen in COVID-19, but do not have the disease.

As more treatments for COVID-19 are developed, researchers from Harvard University have been exploring the benefits of different testing schemes with regards to the new Paxlovid drug.

Study: The impact of recurrent rapid test strategies on the effectiveness of at-home antiviral treatments for SARS-CoV-2. Image Credit: Cryptographer/ShutterstockStudy: The impact of recurrent rapid test strategies on the effectiveness of at-home antiviral treatments for SARS-CoV-2. Image Credit: Cryptographer/Shutterstock


The researchers’ study can be found on the medRxiv* preprint server.

The researchers propose that rapid tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), often lateral flow devices, have found a new use that is particularly valuable against those at risk of severe disease when infected, such as the elderly or immunocompromised.

While the tests tend to be effective at identifying individuals who are infectious, they can also detect infection early enough to make recently developed anti-COVID drugs, such as the Pfizer developed Paxlovid drug, effective.

The researchers have investigated the extent to which rapid testing on a frequent basis can help patients.

The scientists used lateral flow testing (LFT)-associated positivity data and estimated hospitalization risks at days three and five after patients initially show symptoms from the EPIC-HR trial findings from phase two/three. They estimated the test-positivity-probability-weighted risk ratios (RRs) of hospitalization as a function of time since infection, considering the proportion of infected individuals who would be offered the treatment and the proportion of the infected individuals who would manage to take the treatment early enough to receive any benefit. This was estimated for different testing strategies, including once every other day, once every three days, once a week, and once every two weeks.

The sensitivity of the findings to treatment efficacy was also explored, as well as the treatment uptake and coverage/delay from testing positive to treatment.

The results showed that more frequent testing increased the benefits associated with treatment with Paxlovid significantly and that the treatment reduced the risk of hospitalization. The median RR associated with testing every other day was 0.17, compared with 0.77 for the testing every two weeks strategy. This corresponded with an increase in the proportion of the infected population that could benefit from the treatment, from 25.7% of those testing every two weeks to 92.0% for the most effective testing strategy.

As almost all positive tests occur within two weeks of infection, almost all individuals who test positive are captured within this drug efficacy window.

The researchers also found that the benefits of treatment depend not only on treatment coverage, but also on the delay between testing positive and receiving treatment. In order to see RRs within the range of what is observed with full coverage, no delays, and testing every other day, a treatment coverage of 70% would require individuals to be treated within two days of testing positive. This becomes more essential as testing becomes less frequent.

Following this, RRs were fitted based on hospitalization risks at the two treatment initiation times considered in the EPIC-HR trial, assuming a linear decline in efficiency when estimating treatment efficacy levels across a range of delays in treatment since symptoms began.

The scientists did consider trends that could capture different time windows of efficacy beyond the initial range but found no significant changes to the estimated RRs. Nonlinear trends could alter the magnitude of RRs by inflating them towards one if a curvilinear decline was assumed, but this effect was marginal and unlikely to change the observed relative magnitude across strategies.

The CT threshold could also significantly change the results, but the ordering of the RRs across strategies would remain consistent.

Conclusion

The authors have successfully characterized the benefit rapid testing can bring to treatment, with more frequent testing providing the best results. They highlight that reduction in delay from positive tests to treatment is essential, as increases in testing coverage – particularly in communities vulnerable to more severe disease that might suffer from barriers to testing and treatment.

They also argue for this analysis to be continuously revisited as the proportion of vaccinated individuals changes and new variants emerge.

The frequent testing, they propose could reduce the cost of treatments and reduce hospitalizations, and the analysis performed in their paper could help inform drug manufacturers, healthcare workers, and potentially public health policy.

Important notice*

medRxiv publishes preprint papers that have not yet undergone peer review, and the information in this article should not be taken as fact nor used to guide clinical or research practice.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: From Delta to Omicron SARS-CoV-2 variant: switch to saliva sampling for higher detection rate. Image Credit: Marmolejos/Shutterstock

The relative performance of OPS, NPS, and saliva for detecting the Delta and Omicron SARS-CoV-2 variants

by Medical Finance
May 21, 2022
0

Scientists have worked extensively hard to contain the coronavirus disease (COVID-19) pandemic caused by the rapid transmission of severe acute...

Study: Impact of antigen test target failure and testing strategies on the transmission of SARS-CoV-2 variants. Image Credit: Cryptographer/Shutterstock

Study describes the identification of a SARS-CoV-2 variant that escapes detection by antigen tests

by Medical Finance
May 21, 2022
0

In a recent study posted to the Research Square* preprint server and under consideration at a Nature Portfolio Journal, researchers...

Study: Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2. Image Credit: Egoreichenkov Evgenii/Shutterstock

Divalent SARS-CoV-2 fusion vaccine found to be effective in mice

by Medical Finance
May 21, 2022
0

In a recent study published in Vaccines, researchers bioengineered a divalent fusion vaccine by combining the immunogenic region of the...

Study: Antiviral roles of interferon regulatory factor (IRF)-1, 3 and 7 against human coronavirus infection. Image Credit: Corona Borealis Studio/Shutterstock

Antiviral functions of interferon regulatory factors during human coronavirus infection

by Medical Finance
May 21, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers assessed the roles of the interferon (IFN) regulatory factors (IRFs):...

Study: Patterns of presentations of children to emergency departments across Europe and the impact of the COVID-19 pandemic: retrospective observational multinational study. Image Credit: JeannieR/Shutterstock

Study examines pediatric emergency department attendance trends during the first COVID-19 wave in Europe

by Medical Finance
May 21, 2022
0

In a recent study posted to the medRxiv* pre-print server, researchers investigated the impact of severe acute respiratory syndrome coronavirus...

Study: SARS-CoV-2 variants’-Alpha, Delta, and Omicron D614G and P681R/H mutations impact virus entry, fusion, and infectivity. Image Credit: FOTOGRIN / Shutterstock.com

Evaluating effects of D614G and P681R/H mutations on SARS-CoV-2 VOCs

by Medical Finance
May 21, 2022
0

In a recent study posted to the Research Square preprint* server, researchers evaluate how the D614G and P681H mutations alter the...

Next Post
E Coli

How could AI be used to predict infection outcomes?

Testing the Structural Studies Of Biopolymers with the CPMAS Cryoprobe

Testing the Structural Studies Of Biopolymers with the CPMAS Cryoprobe

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • bacteria Sebastian Kaulitzki 46826fb7971649bfaca04a9b4cef3309 620x480
    Microorganisms hindering cancer therapy have more influence than the beneficial ones, study says
  • Antibody 620x480
    Scientists discover antibody that inhibits a broad range of sarbecoviruses
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply